Physician profile
Jonathan Wu
NPI 1225201171
$3,644.99
in general payments reported to CMS, 2019-2025
27 companies · $850 in 2025
The $850 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.31 · 2020: $316 · 2021: $755 · 2022: $359 · 2023: $709 · 2024: $565 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,124.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $589.26 | 2023-2025 | Inspire |
| Genzyme Corporation | $424.21 | 2022-2025 | |
| Acclarent, INC | $349.24 | 2021-2023 | Relieva Spinplus |
| Optinose US, INC. | $341.91 | 2019-2025 | |
| Stryker Corporation | $258.96 | 2019-2023 | Scopis Ent |
| Glaxosmithkline, LLC. | $230.18 | 2021-2025 | Nucala |
| Kaleo, INC. | $210.64 | 2020-2024 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $172.46 | 2021-2025 | Dupixent |
| Integra Lifesciences Corporation | $171.75 | 2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Sanofi-Aventis U.S. LLC | $130.07 | 2020-2022 | |
| Smith+Nephew, INC. | $116.15 | 2020-2025 | Tula, Halo, Ent Sinus |
| Alk-Abello, INC | $115.10 | 2019-2025 | Neffy, Ragwitek, Grastek |
| Takeda Pharmaceuticals U.S.A., INC. | $87.43 | 2021-2022 | |
| Medtronic, INC. | $69.48 | 2023-2024 | Propel, Stealthstation S8 Platform |
| Aerin Medical INC. | $59.37 | 2020-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $41.38 | 2021-2022 | |
| Emd Serono, INC. | $41.25 | 2023 | Mavenclad |
| Arbor Pharmaceuticals, INC. | $37.18 | 2019 | |
| Merck Sharp & Dohme LLC | $36.12 | 2021-2023 | |
| Intersect Ent, INC. | $31.75 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $28.47 | 2025 | Neffy |
| Neurent Medical Limited | $26.10 | 2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Olympus America INC. | $21.73 | 2023 | Olympus |
| Ethicon US, LLC | $18.29 | 2022 | |
| Axogen | $15.30 | 2025 | |
| Cochlear Americas | $12.55 | 2020 | |
| Phathom Pharmaceuticals, INC. | $8.66 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.